KOSEN 한인과학기술자네트워크

Digestive Diseases and Nutrition Primary Sponsor: Department of Health and Human Services Deadline: 4/1/2001; 8/1/2001; 12/1/2001 KEYWORDS Digestive Diseases and Nutrition The Division of Digestive Diseases and Nutrition supports research on the function, diseases and disorders of the digestive tract; the esophagus, stomach, intestine, colon, anorectum, pancreas, liver, gallbladder, and biliary tract; basic, clinical and behavioral research on nutrition and obesity as well as information transfer in the field of digestive diseases and prevention of obesity. Innovative investigator-initiated projects that are not mentioned below are encouraged. Areas that may be of interest to small businesses include, but are not limited to: A. Development of a better method for measuring food intake patterns of individuals that could replace recall. B. Development of better methods for assessing overall nutritional status. C. Development of a non-invasive breath or blood test to accurately measure dietary fat intake. D. Development of biological measures, such as serum or urine tests, for long-term dietary consumption of specific nutrients. E. Development of safe drugs or herbal products that inhibit appetite. F. Development of better means of assessing energy intake and/or energy expenditure (i.e., physical activity), e.g., a device to estimate movement and relate this to calories expended with the goal of impacting behavior and preventing obesity. G. Development of computerized interventions for weight-loss/maintenance and/or increasing physical activity such as hand-held computers and web-based programs. H. Development of devices/equipment/interventions to encourage "activity" while performing sedentary work. I. New technologies for quantitative assessment of intra-abdominal fat; emphasis on technologies that are non-invasive, minimize the use of ionizing radiation, and have the capability of being adapted for use in the usual health care settings. J. Development of more economical methods to produce 18-labelled oxygen for use in energy expenditure studies and/or body composition studies using doubly labeled water. K. Development of better means to detect food borne pathogens with the goals of (1) preventing their inclusion in foodstuffs and (2) better treatment of acute infections. L. Development of new genetic screening methods for detection of inherited digestive and nutritional disorders, e.g., hemochromatosis, Wilson's disease, Crigler-Najar syndrome, Alagille syndrome. M. Development of a non-invasive means of localizing GI bleeding beyond the duodenum that is more sensitive than the Tc-RBC test. N. Development of methods for gastrointestinal endoscopy without the need for sedation. O. Development of molecular probes for the diagnosis of mucosal dysplasia in inflammatory bowel disease. P. Development of new techniques, including non-invasive imaging, to measure motility/intestinal transit at various sites within the gastrointestinal tract. Q. Development, using rationale drug design techniques, of agents that interact with L-type calcium channels or with delayed rectifying potassium channels to treat motility disorders (pseudo-obstructive disorder, chronic constipation, and slow bowel transit). R. Development and validation of herbal, ayurvedic, Chinese traditional, Kampo or other treatments for common GI ailments and liver diseases such as motility disorders, IBD, and cirrhosis. S. Development of pharmaceutics from herbal preparations of promise for therapy of digestive diseases, including liver diseases, involving isolation of active components, preparation of pharmacologically pure preparations, and testing for pharmacokinetics and activity in humans. T. Development of novel antifibrotic therapies for progressive liver failure. U. Development of agents that would protect the gut epithelium from the damage caused by chemotherapeutic agents. V. Development of agents to promote the repair of gut epithelium barrier function, e.g., as needed following chemotherapy. W. Development of techniques for the preservation and transplantation of small intestine and pancreas. X. Development of non-invasive measures of pancreatic exocrine function. Y. Development of drugs for dissolving gallstones in vivo. Z. Development of a test for determining the hepatotoxic potential of drugs, agents or additives that is more sensitive that testing in mice and reflects the humans response to the test compound. AA. Development of animals models to study hepatotoxic agents. BB. Improvements to existing imaging systems, or development of new ones, to allow non-invasive detection of fibrotic, necrotic, inflamed, and fatty in livers prior to transplantation. CC. Development of non-invasve techniques to detect liver disease. DD. Development of non-invasive devices/techniques to measure portal pressure for evaluating portal hypertension in patients with cirrhosis. EE. Development of a rapid, non-invasive diagnostic test for biliary atresia. FF. Development of an extracorporeal liver assist device to provide temporary therapeutic assistance in cases such as fulminant hepatic failure or drug overdose. GG. Development of non-occluding stents for use in the biliary tract and in transjugular intra-hepatic porto-systemic shunts (TIPS). HH. Development of cryopreservation techniques for human hepatocytes that would maximize viability and cell culture growth potential of thawed cells. II. Creation of artificial organs or development of effective xenographic techniques for liver transplantation. JJ. Development of molecular standards for Hepatitis C virus quantitation and typing. KK. Development of molecular standards for Hepatitis B virus quantitation and typing. For additional information on research topics, contact: Diabetes, Endocrinology and Metabolic Diseases Dr. Barbara Linder National Institute of Diabetes and Digestive and Kidney Diseases Democracy 2, Room 699 Bethesda, MD 20892 (301) 594-0021; Fax: (301) 480-3503 Email: bl99n@nih.gov Digestive Diseases and Nutrition Dr. Judith Podskalny National Institute of Diabetes and Digestive and Kidney Diseases Democracy 2, Room 667 (301) 594-8876; Fax: (301) 480-8300 Email: jp53s@nih.gov Kidney, Urologic and Hematologic Diseases Dr. James Scherbenske National Institute of Diabetes and Digestive and Kidney Diseases Democracy 2, Room 613 Bethesda, MD 20892 (301) 594-7719; Fax: (301) 480-3510 Email: js255f@nih.gov For administrative and business management questions, contact: Mr. George Tucker, M.B.A. Grants Management Specialist National Institute of Diabetes and Digestive and Kidney Diseases Democracy 2, Room 635 (301) 594-8853; Fax: (301) 480-3504 Email: gt35v@nih.gov NOTE: The Solicitations listed on this site are partial copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should always use the suggested links on our reference pages. These will take you directly to the appropriate agency information where you can read the official version of the solicitation you are interested in. The official link for this page is: http://grants.nih.gov/grants/funding/sbir.htm. Solicitation closing dates are: April 1, August 1, and December 1, 2001.